The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

Tech in AsiaAsia

Tencent-linked investor takes stake in China’s AI drug startup

October 16

Tencent backed XtalPi in 2018 and runs the Tencent iDrug platform.

Funding & deals

Read at Tech in Asia ↗

One letter a week, starting soon.

Latest

Tencent-linked investor takes stake in China’s AI drug startup

Related

ValleyNorth.cloud bags $60M in funding to help businesses keep runaway cloud costs in check SiliconANGLE

ValleyMueon nabs $65M in funding to develop 3D computing modules SiliconANGLE

ValleyWhen it came to Cal AI’s viral success, a small army of influencers paid off TechCrunch AI

AsiaHong Kong investors most eager in Asia to beat markets – but temper return hopes: report SCMP Tech

ValleyRamp raises $1.85B as it expands beyond finance software SiliconANGLE

SiliconJapan Offers GlobalFoundries $21B for U.S. Fab Expansion EE Times